the health
Gettyimages.ru © PA Images / Victoria Jones
The results of clinical trials showed, on Thursday, that the survival rates of patients with severe “Covid” can improve and stay in intensive care up to 10 days using existing arthritis medications.
Roche’s Actemra and Sanofi’s Kevzara – both immunosuppressive drugs – lowered death rates among the sickest Covid patients by 8.5 percentage points, according to the results, which have yet to be revised.
In response to the apparent breach, the UK government is immediately making drugs available to doctors. A spokesperson said the move could ease pressure on the NHS (the National Health Administration), “potentially saving hundreds of lives.”
read more
Deputy Chief Medical Officer in England, Professor Jonathan Van Tamm, said the news was “an important step forward to increase the survival rate of patients in intensive care with” Covid-19 “.
The results come from a study of 800 critically ill Coronavirus patients, and it is part of the international REMAP-CAP trial that focuses on treatments for acute lung infections.
The results showed that deaths decreased from 35.8% in the control group to 27.3% for those who were given tocilizumab or sarilumab.
Professor Anthony Gordon, of Imperial College London, who co-led the study, said: “This is a major change in survival rates. Both are life-saving drugs.”
During the pandemic, the steroid dexamethasone was used to treat some seriously ill coronavirus patients, while the US Food and Drug Administration allowed some antibody drugs for patients who are not in the hospital.
It also approved the anti-viral drug Remdesivir, made by the biotechnology company Gilead, for use in the most dangerous “Covid” patients, although the World Health Organization said there was not enough evidence to show that it increased survival rates.
Source: RT
Source link